multiple sclerosis

Atara Reports Initial Data for Multiple Sclerosis Candidate
Yahoo/Zacks.com
Mon, 07/1/19 - 10:18 am
Atara
ATA188
clinical trials
multiple sclerosis
Novartis wins Gilenya reprieve as judge blocks generics, for now
Yahoo/Reuters
Tue, 06/25/19 - 09:20 am
Novartis
generics
Gilenya
multiple sclerosis
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Thu, 06/6/19 - 09:53 am
Celgene
FDA
EMA
ozanimod
multiple sclerosis
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Thu, 05/30/19 - 09:42 am
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
Upcoming events – key tests approach for Biogen and Kalvista
EP Vantage
Fri, 05/24/19 - 10:42 am
Biogen
BIIB098
Tecfidera
multiple sclerosis
KalVista
HAE
Biocryst
BCX7353
KVD900
Upcoming events – Phase III data for Chiasma and Novartis
EP Vantage
Fri, 05/17/19 - 07:23 pm
Chiasma
acromegaly
Mycapssa
clinical trials
multiple sclerosis
Novartis
ofatumumab
Sanofi Joins Drugmakers' Bid to Treat Patients With Software
Yahoo/Bloomberg
Wed, 05/15/19 - 10:26 am
Sanofi
digital pharma
Happify Health
digital therapeutics
depression
multiple sclerosis
Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients
Endpoints
Thu, 05/9/19 - 10:43 am
Novartis
Mayzent
siponimod
multiple sclerosis
FDA Raises Concerns With Novartis in Clinical Inspection
RAPS.org
Mon, 05/6/19 - 07:30 pm
Novartis
FDA
Mayzent
siponimod
clinical trials
multiple sclerosis
German Merck finally gets yes for MS drug Mavenclad
Biopharma Dive
Tue, 04/2/19 - 04:20 pm
FDA
Merck KGaA
Mavenclad
MS
multiple sclerosis
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Endpoints
Sun, 03/31/19 - 03:53 pm
FDA
Merck KGaA
cladribine
MA
multiple sclerosis
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Wed, 03/27/19 - 10:20 am
Celgene
ozanimod
MS
multiple sclerosis
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Wed, 03/13/19 - 10:13 am
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Mon, 03/11/19 - 10:25 pm
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
CP WIre
Mon, 02/25/19 - 12:24 pm
Alkermes
Biogen
diroximel fumarate
MS
multiple sclerosis
Blocking brain inflammation in multiple sclerosis with gut immune cells
Fierce Biotech
Fri, 01/4/19 - 09:08 am
inflammation
MS
multiple sclerosis
Alkermes/Biogen hope for less tummy trouble with new MS pill
Pharmaforum
Tue, 12/18/18 - 10:28 am
Alkermes
Biogen
MS
multiple sclerosis
Vumerity
Novartis confident in Gilenya despite FDA call out
Biopharma Dive
Wed, 11/21/18 - 01:09 pm
Novartis
Gilenya
MS
multiple sclerosis
Mylan's generic Copaxone wins in court, but market barriers remain
Biopharma Dive
Mon, 10/15/18 - 12:13 pm
Teva Pharmaceutical
Copaxone
patents
MS
multiple sclerosis
Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions
Endpoints
Fri, 10/12/18 - 12:20 pm
Merck KGaA
evobrutinib
MS
multiple sclerosis

Pages